NCT00237900View on ClinicalTrials.gov

Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

February 29, 2004

Conditions
Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC
Interventions
DRUG

Gefitinib, 5-fluorouracil, leucovorin and radiotherapy

Trial Locations (1)

Unknown

Reseach Site, Helsinki

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY